WallStSmart

DaVita HealthCare Partners Inc (DVA)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 298077% more annual revenue ($13.64B vs $4.58M). DVA leads profitability with a 5.5% profit margin vs 3.8%. DVA earns a higher WallStSmart Score of 66/100 (B-).

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22

NIVF

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued
NIVFUndervalued (+100.0%)

Margin of Safety

+100.0%

Fair Value

$3305.41

Current Price

$2.01

$3303.40 discount

UndervaluedFair: $3305.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

NIVF1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NIVF4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$983,3203/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.6%3/10

ROE of 1.6% — below average capital efficiency

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bull Case : NIVF

The strongest argument for NIVF centers on Price/Book.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Return on Equity. Thin 3.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

DVA carries more volatility with a beta of 0.93 — expect wider price swings.

DVA is growing revenue faster at 9.9% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (66/100 vs 51/100). NIVF offers better value entry with a 100.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a prominent provider in the reproductive health sector, specializing in advanced fertility solutions and innovative in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive techniques and addresses the growing global demand for fertility treatments through a well-established network of clinics and strategic partnerships. Positioned for growth within a rapidly expanding market, NIVF is well-equipped to capitalize on emerging opportunities, reinforcing its commitment to helping individuals and couples realize their dreams of parenthood.

Want to dig deeper into these stocks?